Christina M. Annunziata

Women's Malignancies Branch, National Cancer Institute

Affiliated withNational Cancer Institute

Research Area

Biography

Christina M. Annunziata has not added Biography.
If you are Christina M. Annunziata and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 30	2015

Other Publications

Article	Year
Is there a genomic basis for primary chemoresistance in ovarian cancer? Gynecologic oncology\| PubMed ID: 12821333	2003
Proteomics in clinical trials and practice: present uses and future promise. Molecular & cellular proteomics : MCP\| PubMed ID: 16737951	2006
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer cell\| PubMed ID: 17692804	2007
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18006758	2007
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer\| PubMed ID: 18300236	2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18669456	2008
Uterine papillary serous carcinoma: a new paradigm for treatment? Cancer\| PubMed ID: 19452535	2009
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood\| PubMed ID: 19965618	2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20068097	2010
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer research\| PubMed ID: 20424119	2010
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer\| PubMed ID: 20564628	2010
CD157 in ovarian carcinoma: how does it help us? Journal of the National Cancer Institute\| PubMed ID: 20639477	2010
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20823142	2010
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 biology reports\| PubMed ID: 20948822	2010
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood\| PubMed ID: 21163924	2011
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance the... American journal of therapeutics\| PubMed ID: 21248621	2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investigational new drugs\| PubMed ID: 22370972	2012
IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer research\| PubMed ID: 22942254	2012
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 23236152	2012
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Molecular & cellular proteomics : MCP\| PubMed ID: 23449826	2013
Novel facts about FAK: new connections to drug resistance? Journal of the National Cancer Institute\| PubMed ID: 24062526	2013
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Molecular and clinical oncology\| PubMed ID: 24649212	2013
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. PloS one\| PubMed ID: 24748377	2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute\| PubMed ID: 24842883	2014
The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells. Cancer cell international\| PubMed ID: 25324692	2014
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. Oncotarget\| PubMed ID: 25474241	2014